Navigation Links
Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon

Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities and clinical trials, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. Government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

CONTACT: Jerry Parrott, Vice President, Corporate Communications,+1-301-315-2777, Kate de Santis, Director, Inv
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:12/24/2014)... DALLAS , Dec. 23, 2014  Lockton ... operation of Lockton Companies, announced the addition of ... Foerster will join Lockton Dunning,s Pharmacy Consulting team, ... years of relevant industry experience to the position.  ... Managed Market Sales at Diplomat Specialty Pharmacy, where ...
(Date:12/24/2014)... 2014  Medical Science Liaisons play a large role ... the medical device industry and key stakeholders, the role ... years as the device industry relies on them to ... by benchmarking firm, Best Practices, LLC, one area where ... is by harnessing new technology to enable education. Online ...
(Date:12/22/2014)... --  TRU-D SmartUVC LLC, producers of the first ... that the General Services Administration has awarded the company ... This newly formed agreement will allow TRU-D SmartUVC ... including Department of Veteran Affairs and Department of Defense ... solutions for the Ebola effort in West ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2
(Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas Sale, ... has chosen their best-selling lace wedding dresses, vintage bridesmaid ... season. , Now, BellasDress.com features popular women’s dresses, ... discount prices. The business hopes everyone can have a ... , “All our elegant products are made with exquisite ...
(Date:12/25/2014)... 2014 Recently, LunaDress.co.uk has updated its blog to ... accessories. Now, all of the models at LunaDress.co.uk come with big ... lifts the wedding veil can turn out to be a most ... wedding veil can always bring surprise to a wedding. On the ... to choose veils for a big day . , Going ...
(Date:12/25/2014)... (HealthDay News) -- Among early stage breast cancer patients ... of one percent will eventually develop leukemia as a ... The finding comes from a review of more than ... and it suggests that the risk for developing treatment-related ... previously thought. "The frequency of bone marrow cancers ...
(Date:12/25/2014)... ” was featured on NewsWatch as part of its monthly ... the iOS, Android, and Windows markets. Andrew Tropeano, a mobile ... and shared with viewers how this is an application for ... “A picture says a thousand words.” It’s true. There are ... because each picture holds a unique and special meaning. Photos ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... as primary prevention did not appear to significantly reduce ... cerebrovascular and peripheral vascular events in patients with type ... JAMA . However, aspirin did significantly reduce the combination ... is being released early online Sunday, November 9 to ...
... of a new Chantix risk that may be causing patients to ... well. In addition to seizures, Chantix has also been under investigation ... ... Denver (PRWEB) November 4, 2008 -- LegalView, the number one ...
... for MP3 players placed within an inch of pacemakers ... devices, according to research presented at the American Heart ... effects of MP3 player headphones, most of which contain ... cardiac devices (abstract P662). , An MP3 player is ...
... Pa., Nov. 9 The NHS Human,Services Foundation held ... 2008 at the Hyatt Regency Penn,s Landing in Philadelphia. ... Foundation, which supports the mission,of NHS Human Services, one ... the country., Every year the Foundation presents the ...
... Glaucoma-related highlights of today,s scientific program of the 2008 ... and European Society of Ophthalmology (SOE) include a study ... carotid artery narrowing and potentially elevated risk for stroke, ... of fasting, common to the world,s seven major religions, ...
... of patients in need of organ transplants on the ... unconventional sources for organs. Individuals are willing to donate ... where the poverty rate is high, resulting in numerous ... This troubling issue will be the topic of a ...
Cached Medicine News:Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 2Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 3Health News:Low-dose aspirin does not appear to reduce risk of CV events in patients with diabetes 4Health News:LegalView Informs Chantix Patients of Risk of Seizures Leading to Traffic Accidents 2Health News:LegalView Informs Chantix Patients of Risk of Seizures Leading to Traffic Accidents 3Health News:LegalView Informs Chantix Patients of Risk of Seizures Leading to Traffic Accidents 4Health News:MP3 headphones interfere with implantable defibrillators, pacemakers 2Health News:MP3 headphones interfere with implantable defibrillators, pacemakers 3Health News:Gala Raises Funds for NHS Human Services 2Health News:AAO-SOE Joint Meeting Nov. 9 glaucoma research highlights 2Health News:AAO-SOE Joint Meeting Nov. 9 glaucoma research highlights 3Health News:AAO-SOE Joint Meeting Nov. 9 glaucoma research highlights 4Health News:Transplant experts convene at ASN Renal Week 2008 to discuss organ trafficking 2
... offers an economical, ... alternative to existing ... guarantees accurate and ... the time-consuming recalibration ...
... 1296-041 DELFIA Plate Dispense allows the ... to all wells or to selected ... To minimize background and to avoid ... optimized for use with DELFIA Enhancement ...
... Precision 2000 ... innovative solution for ... liquid handling. With ... perform virtually any ...
Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag...
Medicine Products: